Financials in USD. Standardized financial statements.
A compact view of how Ocular Therapeutix, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $51.82M | $63.72M | $58.44M | $51.49M | $43.52M | $17.40M | $4.23M | $1.99M | $1.92M | $1.89M |
| Revenue Growth? | -18.7% | +9.0% | +13.5% | +18.3% | +150.1% | +311.7% | +112.4% | +3.5% | +1.9% | 0.0% |
| Cost of Revenue? | $6.57M | $5.63M | $5.28M | $4.54M | $4.41M | $2.08M | $2.33M | $465,000 | $457,000 | $443,000 |
| Gross Profit? | $45.25M | $58.10M | $53.16M | $46.95M | $39.12M | $15.32M | $1.90M | $1.52M | $1.47M | $1.44M |
| Gross Margin? | +87.3% | +91.2% | +91.0% | +91.2% | +89.9% | +88.0% | +45.0% | +76.6% | +76.2% | +76.5% |
| Operating Expenses? | $315.39M | $229.88M | $135.54M | $125.61M | $117.15M | $78.17M | $87.70M | $60.64M | $63.39M | $44.77M |
| Operating Income? | -$270.02M | -$171.78M | -$82.38M | -$78.65M | -$78.04M | -$62.85M | -$85.80M | -$59.12M | -$61.92M | -$43.33M |
| EBITDA? | -$249.78M | -$176.14M | -$66.42M | -$61.91M | $2.54M | -$146.09M | -$77.74M | -$55.95M | -$59.87M | -$42.14M |
| Income Before Tax | -$265.94M | -$193.51M | -$80.74M | -$71.04M | -$6.55M | -$155.64M | -$86.37M | -$59.98M | -$63.39M | -$44.70M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$2.29M | $272,000 | $0 |
| Net Income? | -$265.94M | -$193.51M | -$80.74M | -$71.04M | -$6.55M | -$155.64M | -$86.37M | -$57.69M | -$63.39M | -$44.70M |
| EPS? | $-1.42 | $-1.22 | $-1.09 | $-1.04 | $-1.05 | $-2.56 | $-1.91 | $-1.57 | $-2.20 | $-1.80 |
| Diluted EPS? | $-1.42 | $-1.22 | $-1.02 | $-0.97 | $-0.98 | $-2.56 | $-1.91 | $-1.57 | $-2.20 | $-1.80 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality